Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Treatment of fistulizing Crohn's disease].
Tonkić A, Borzan V. Tonkić A, et al. Among authors: borzan v. Acta Med Croatica. 2013 Apr;67(2):191-4. Acta Med Croatica. 2013. PMID: 24471302 Review. Croatian.
[Croatian consensus on the treatment of inflammatory bowel diseases with biologic therapy].
Vucelić B, Cuković-Cavka S, Banić M, Bilić A, Borzan V, Duvnjak M, Katicić M, Kolacek S, Krznarić Z, Kujundzić M, Marusić M, Mihaljević S, Mijandrusić BS, Persić M, Simunić M, Skurla B, Stimac D, Tonkić A, Troskot B. Vucelić B, et al. Among authors: borzan v. Acta Med Croatica. 2013 Apr;67(2):75-87. Acta Med Croatica. 2013. PMID: 24471291 Croatian.
[Croatian guidelines for use of enteral nutrition in Crohn's disease].
Krznarić Z, Kolacek S, Bender DV, Kelecić DL, Cuković-Cavka S, Sincić BM, Banić M, Borzan V, Simunić M, Persić M, Stimac D, Vucelić B. Krznarić Z, et al. Among authors: borzan v. Lijec Vjesn. 2010 Jan-Feb;132(1-2):1-7. Lijec Vjesn. 2010. PMID: 20359151 Croatian.
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Panés J; HIBISCUS Study Group. Rubin DT, et al. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):17-27. doi: 10.1016/S2468-1253(21)00338-1. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798036 Clinical Trial.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Sandborn WJ, et al. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. N Engl J Med. 2021. PMID: 34587385 Clinical Trial.
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
21 results